PDF(Pubmed)
Abstract：
UNASSIGNED: Small bowel (SB) capsule endoscopy (SBCE) is a sensitive modality for screening the entire SB of patients with Crohn\'s disease (CD); however, the prognostic impact of the results is unclear. We evaluated the ability of the SBCE score to predict therapeutic intervention for patients with CD and SB lesions without clinical symptoms as well as negative C-reactive protein (CRP) levels.
UNASSIGNED: Fifty-six patients who underwent a patency evaluation and had a CD activity index (CDAI) score <150 mg/dL and CRP level <0.5 mg/dL were included. Twenty-one and 35 patients had CD classified as Montreal classifications L1 and L3, respectively. The initial SBCE scores were subsequently grouped according to the presence or absence of intervention based on cutoff values. We examined whether the scores could predict the need for therapeutic intervention at 1 year, 2 years, and 5 years. The CD activity in capsule endoscopy (CDACE) score was used as the SBCE score.
UNASSIGNED: The median observation period was 1,326 days. Twenty-one patients received therapeutic intervention. There were significant differences between patients with and without treatment intervention according to the CDACE cutoff value of 420 at 1 year, 2 years, and 5 years. Significant differences between patients with Montreal classification L1 with and without intervention were observed at 1 year and 2 years. The CDACE score was moderately and strongly correlated with the Lewis score and capsule endoscopy CDAI score, respectively (Spearman rank correlation coefficient: ρ = 0.6462 and ρ = 0.9199, respectively; p < 0.0001).
UNASSIGNED: A CDACE score ≥420 is predictive of intervention after 1 year for patients with CD, a CDAI score <150, and a CRP level <0.5 mg/dL. A larger study with a prospective design is necessary to validate our findings.
UNASSIGNED: Fifty-six patients who underwent a patency evaluation and had a CD activity index (CDAI) score <150 mg/dL and CRP level <0.5 mg/dL were included. Twenty-one and 35 patients had CD classified as Montreal classifications L1 and L3, respectively. The initial SBCE scores were subsequently grouped according to the presence or absence of intervention based on cutoff values. We examined whether the scores could predict the need for therapeutic intervention at 1 year, 2 years, and 5 years. The CD activity in capsule endoscopy (CDACE) score was used as the SBCE score.
UNASSIGNED: The median observation period was 1,326 days. Twenty-one patients received therapeutic intervention. There were significant differences between patients with and without treatment intervention according to the CDACE cutoff value of 420 at 1 year, 2 years, and 5 years. Significant differences between patients with Montreal classification L1 with and without intervention were observed at 1 year and 2 years. The CDACE score was moderately and strongly correlated with the Lewis score and capsule endoscopy CDAI score, respectively (Spearman rank correlation coefficient: ρ = 0.6462 and ρ = 0.9199, respectively; p < 0.0001).
UNASSIGNED: A CDACE score ≥420 is predictive of intervention after 1 year for patients with CD, a CDAI score <150, and a CRP level <0.5 mg/dL. A larger study with a prospective design is necessary to validate our findings.
摘要：
■小肠（SB）胶囊内窥镜检查（SBCE）是筛查克罗恩病（CD）患者的整个SB的敏感方式；但是，结果对预后的影响尚不清楚.我们评估了SBCE评分预测无临床症状和C反应蛋白（CRP）水平阴性的CD和SB病变患者治疗干预的能力。
■纳入56例接受通畅性评估且CD活性指数(CDAI)评分<150mg/dL且CRP水平<0.5mg/dL的患者。21例和35例患者的CD分别分类为蒙特利尔分类L1和L3。随后根据是否存在基于截止值的干预对初始SBCE评分进行分组。我们检查了分数是否可以预测1年时治疗干预的需要，2年,和5年。采用胶囊内镜下CD活性(CDACE)评分作为SBCE评分。
■中位观察期为1326天。21例患者接受治疗干预。根据1年时420的CDACE截止值，有和没有治疗干预的患者之间存在显着差异。2年,和5年。在1年和2年观察到有和没有干预的蒙特利尔L1分类患者之间的显着差异。CDACE评分与Lewis评分和胶囊内镜CDAI评分呈中等相关性,分别(Spearman秩相关系数：ρ=0.6462和ρ=0.9199；p<0.0001)。
■CDACE评分≥420可预测CD患者1年后的干预，CDAI评分<150，CRP水平<0.5mg/dL。具有前瞻性设计的更大研究对于验证我们的发现是必要的。
■纳入56例接受通畅性评估且CD活性指数(CDAI)评分<150mg/dL且CRP水平<0.5mg/dL的患者。21例和35例患者的CD分别分类为蒙特利尔分类L1和L3。随后根据是否存在基于截止值的干预对初始SBCE评分进行分组。我们检查了分数是否可以预测1年时治疗干预的需要，2年,和5年。采用胶囊内镜下CD活性(CDACE)评分作为SBCE评分。
■中位观察期为1326天。21例患者接受治疗干预。根据1年时420的CDACE截止值，有和没有治疗干预的患者之间存在显着差异。2年,和5年。在1年和2年观察到有和没有干预的蒙特利尔L1分类患者之间的显着差异。CDACE评分与Lewis评分和胶囊内镜CDAI评分呈中等相关性,分别(Spearman秩相关系数：ρ=0.6462和ρ=0.9199；p<0.0001)。
■CDACE评分≥420可预测CD患者1年后的干预，CDAI评分<150，CRP水平<0.5mg/dL。具有前瞻性设计的更大研究对于验证我们的发现是必要的。
